Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

66.7%

2 terminated/withdrawn out of 3 trials

Success Rate

33.3%

-53.2% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

200%

2 of 1 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 1
1(50.0%)
N/A
1(50.0%)
2Total
Phase 1(1)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT05366010Not ApplicableTerminated

Oscillation and Lung Expansion (OLE) Therapy for Treatment of Neuromuscular Disease (NMD) Patients

Role: collaborator

NCT05349019Terminated

A Natural History Study of Patients With G2019S LRRK2 Parkinson's Disease

Role: collaborator

NCT03450369Phase 1Completed

A Study of the Safety, Engraftment, and Action of NB01 in Adults With Moderate Acne

Role: collaborator

All 3 trials loaded